Trial Profile
A double-blind, placebo-controlled, parallel, randomized study to evaluate the efficacy and safety of 3 oral dose levels of TMI-005 [apratastat] in subjects with active rheumatoid arthritis on a background of methotrexate
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Apratastat (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Wyeth; Wyeth Pharmaceuticals
- 11 Oct 2005 New trial record.